Osamu Ubukata

Daiichi Sankyo RD Novare Co, Ltd, 1-16-13 Kitakasai
Tokyo, 1348630, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Suppression of TDP-43 aggregation by artificial peptide binder targeting to its low complexity domain.

Suppression of TDP-43 aggregation by artificial peptide binder targeting to its low complexity domain.

Journal: Biochemical and biophysical research communications

Published: April 12, 2023

Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.

Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.

Journal: Journal of medicinal chemistry

Published: December 26, 2022

Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.

Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.

Journal: Biochemical and biophysical research communications

Published: June 16, 2022

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.

Journal: Molecular cancer therapeutics

Published: May 02, 2022

Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.

Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.

Journal: Bioorganic & medicinal chemistry letters

Published: January 23, 2022

Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).

Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).

Journal: FEBS letters

Published: November 13, 2019

A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1.

A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1.

Journal: Acta crystallographica. Section F, Structural biology communications

Published: December 09, 2017

Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.

Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.

Journal: Bioorganic & medicinal chemistry

Published: February 25, 2017

Discovery of a compound that acts as a bacterial PyrG (CTP synthase) inhibitor.

Discovery of a compound that acts as a bacterial PyrG (CTP synthase) inhibitor.

Journal: Journal of medical microbiology

Published: June 16, 2012

Discovery of a compound which acts as a bacterial UMP kinase PyrH inhibitor.

Discovery of a compound which acts as a bacterial UMP kinase PyrH inhibitor.

Journal: FEMS microbiology letters

Published: February 07, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026